School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.
Front Endocrinol (Lausanne). 2023 Jan 25;14:1120774. doi: 10.3389/fendo.2023.1120774. eCollection 2023.
Chemerin as an inflammatory biomarker has gained attention in its biomarker capability. Several studies measured its levels in chronic kidney disease (CKD), as one of the common non-communicable causes of mortality and morbidity. Hence, this systematic review and meta-analysis aimed to investigate this association.
PubMed, Scopus, Embase, and the Web of Science databases were systematically searched for studies investigating chemerin levels in any CKD stage (including end-stage renal disease patients undergoing hemodialysis (HD)) and comparing it with healthy controls. Random effect meta-analysis was performed to calculate the standardized mean difference (SMD) and 95% confidence interval (CI).
A total of eight studies were included, comprised of 875 individuals, with a mean age of 56.92 ± 11.78 years. All studies had high quality based on the New Castle-Ottawa Scale (NOS). Meta-analysis revealed significantly higher levels of chemerin in CKD patients compared to healthy controls (SMD 2.15, 95% CI 0.83-3.48, p-value<0.01). Additionally, HD patients had statistically higher levels of chemerin than controls (SMD 2.10, 95% CI 0.58-3.62, p-value=0.01). In meta-regression, publication year accounted for 23.50% and 24.17% of heterogeneity for these analyses, respectively.
Chemerin can be potentially used as a biomarker in CKD patients, which can suggest the inflammatory pathways for the disease. Further research is warranted for the assessment of its clinical applications and enlightening its role in the pathophysiology of CKD.
趋化素作为一种炎症生物标志物，其作为生物标志物的能力引起了关注。一些研究测量了其在慢性肾脏病（CKD）中的水平，CKD 是常见的非传染性死亡和发病原因之一。因此，本系统评价和荟萃分析旨在研究这种相关性。
系统检索了 PubMed、Scopus、Embase 和 Web of Science 数据库中研究趋化素水平的研究，这些研究包括任何 CKD 阶段（包括接受血液透析（HD）的终末期肾病患者）并将其与健康对照组进行比较。采用随机效应荟萃分析计算标准化均数差（SMD）和 95%置信区间（CI）。
共纳入 8 项研究，包括 875 名参与者，平均年龄为 56.92±11.78 岁。所有研究根据纽卡斯尔-渥太华量表（NOS）均为高质量。荟萃分析显示，CKD 患者的趋化素水平明显高于健康对照组（SMD 2.15，95%CI 0.83-3.48，p<0.01）。此外，HD 患者的趋化素水平明显高于对照组（SMD 2.10，95%CI 0.58-3.62，p=0.01）。在元回归分析中，发表年份分别解释了这两种分析中 23.50%和 24.17%的异质性。
趋化素可作为 CKD 患者的潜在生物标志物，提示疾病的炎症途径。需要进一步研究以评估其临床应用，并阐明其在 CKD 病理生理学中的作用。
